Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Perspectives of Neuro-COVID: Myasthenia.

Literature DB >> 33732209

Perspectives of Neuro-COVID: Myasthenia.

Josef Finsterer¹, Fulvio A Scorza².

Abstract

Entities: Chemical Disease Gene Species

Keywords: COVID-19; SARS- CoV-2; myastheic syndrome; myasthenia; pathophysiology

Year: 2021 PMID： 33732209 PMCID： PMC7959778 DOI： 10.3389/fneur.2021.635747

Source DB: PubMed Journal: Front Neurol ISSN： 1664-2295 Impact factor: 4.003

× No keyword cloud information.

31 in total

1. Management of patients with generalised myasthenia gravis and COVID-19: four case reports.

Authors: Annemarie Hübers; Agustina M Lascano; Patrice H Lalive
Journal: J Neurol Neurosurg Psychiatry Date: 2020-07-10 Impact factor: 10.154

2. Speculative clues on Myasthenia gravis and COVID-19.

Authors: C Scoppetta; S Casciato; G Di Gennaro
Journal: Eur Rev Med Pharmacol Sci Date: 2020-08 Impact factor: 3.507

3. Myasthenic Syndrome Caused by Hydroxychloroquine Used for COVID-19 Prophylaxis.

Authors: Guray Koc; Zeki Odabasi; Ersin Tan
Journal: J Clin Neuromuscul Dis Date: 2020-09

4. The CALL Score for Predicting Outcomes in Patients With COVID-19.

Authors: Elisa Grifoni; Alice Valoriani; Francesco Cei; Vieri Vannucchi; Federico Moroni; Lorenzo Pelagatti; Roberto Tarquini; Giancarlo Landini; Luca Masotti
Journal: Clin Infect Dis Date: 2021-01-23 Impact factor: 9.079

5. [Treatment of Multiple Sclerosis, Neuromyelitis Optica Spectrum Disorder and Myasthenia Gravis during the COVID-19 Pandemic].

Authors: Masashi Nakamura; Ichiro Nakashima
Journal: Brain Nerve Date: 2020-10

6. Diagnosing myasthenic crisis in SARS-CoV-2 infected patients requires adherence to appropriate criteria.

Authors: Josef Finsterer; Fulvio A Scorza; Carla A Scorza
Journal: J Neurol Sci Date: 2020-07-27 Impact factor: 3.181

7. Myasthenic crisis in COVID-19.

Authors: Fadi Delly; Maryam J Syed; Robert P Lisak; Deepti Zutshi
Journal: J Neurol Sci Date: 2020-05-06 Impact factor: 3.181

8. COVID-19-associated risks and effects in myasthenia gravis (CARE-MG).

Authors: Srikanth Muppidi; Jeffrey T Guptill; Saiju Jacob; Yingkai Li; Maria E Farrugia; Amanda C Guidon; Jinny O Tavee; Henry Kaminski; James F Howard; Gary Cutter; Heinz Wiendl; Matthew B Maas; Isabel Illa; Renato Mantegazza; Hiroyuki Murai; Kimiaki Utsugisawa; Richard J Nowak
Journal: Lancet Neurol Date: 2020-12 Impact factor: 44.182

Perspectives of Neuro-COVID: Myasthenia.

1. Management of patients with generalised myasthenia gravis and COVID-19: four case reports.

2. Speculative clues on Myasthenia gravis and COVID-19.

3. Myasthenic Syndrome Caused by Hydroxychloroquine Used for COVID-19 Prophylaxis.

4. The CALL Score for Predicting Outcomes in Patients With COVID-19.

5. [Treatment of Multiple Sclerosis, Neuromyelitis Optica Spectrum Disorder and Myasthenia Gravis during the COVID-19 Pandemic].

6. Diagnosing myasthenic crisis in SARS-CoV-2 infected patients requires adherence to appropriate criteria.

7. Myasthenic crisis in COVID-19.

8. COVID-19-associated risks and effects in myasthenia gravis (CARE-MG).

9. COVID-19 in patients with myasthenia gravis.

Review 1. The relationship between myasthenia gravis and COVID-19: a systematic review.

2. Not the Virus but Treatment and Immune Response Cause SARS-CoV-2-associated Neuropathy.

3. Clinical Onset and Multiple Sclerosis Relapse after SARS-CoV-2 Infection.